A Phase 1 Study of ZSP1241 in Participants With Advanced Solid Tumors
Status:
Recruiting
Trial end date:
2021-10-31
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety, tolerability and pharmacokinetics, and
determine the maximum tolerated dose of ZSP1241 in participants with hepatocellular
carcinoma, cholangiocarcinoma, gastric cancer, esophageal cancer, colorectal cancer and other
advanced solid tumors.